|FluoroPharma Medical, Inc.|
8 Hillside Avenue
United States - Map
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology in the United States. The companys product portfolio includes BFPET, an imaging agent that has completed Phase Ia clinical trials in stress-testing for patients with known or suspected coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase II clinical trials to assess myocardial metabolism for patients with CAD. It is also developing candidates for use in the detection and treatment of vulnerable plaque. The company has license agreement with Massachusetts General Hospital. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.
|Dr. Thomas H. Tulip Ph.D.,
Chief Exec. Officer, Pres and Director
|Ms. Tamara Rhein ,
Chief Financial Officer and Principal Accounting Officer
|Mr. Edward L. Lyons Jr.,
VP of Devel.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|